NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054.


In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

MeSH terms

  • Adult
  • Antigens, CD19
  • Humans
  • Immunoconjugates* / therapeutic use
  • Immunotherapy, Adoptive / methods
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Non-Hodgkin* / drug therapy


  • Antigens, CD19
  • Immunoconjugates